Bliss GVS Pharma Ownership Change: New Promoters Take Control

• Acquirers hold 47.95% equity stake.
• Managing Director resigns following control transfer.

Reader Takeaway: New ownership brings structural board changes, shifting control from outgoing management to Anupam Rasayan and Mates Visa.

What just happened

Bliss GVS Pharma has officially consummated its Share Purchase Agreement (SPA) dated May 23, 2026. Mates Visa Consultancy Private Limited acquired over 50.98 million equity shares, while Anupam Rasayan India Limited secured additional shares through an open offer. Together, the entities now hold a 47.95% stake in the company, establishing them as the new promoters effective September 28, 2026.

Why this matters

This transaction signals a total transition in leadership and governance. Managing Director Narsimha Shibroor Kamath has resigned from his post, facilitating the handoff to the incoming management team. The company’s strategic direction is expected to align with the expertise of its new controlling shareholders.

New Board Appointments

Three new Additional Directors have joined the board as Non-Executive Non-Independent Directors:

• Mr. Hetul Krishnakant Mehta: Brings 30 years of experience in bulk drug manufacturing.
• Mr. Amar Dilip Shah: Provides expertise in marketing, sales, and business development.
• Mr. Pramod Badrinarayan Kasat: Offers deep experience in investment banking, structured finance, and credit markets.

Next steps

Shareholder approval for the appointment of these new directors will be sought via a Postal Ballot. The company is currently finalizing the notice, which will be dispatched to members in line with regulatory requirements.